Displaying 1121 - 1140 of 1557
DaVita, Inc.
Exclusion Payments to Settle Pharmaceutical Patent Cases: They're B-a-a-a-ck!
Bureau of Competition Issues FY 2005 Summary of Pharmaceutical Company Settlement Agreements
Allergan, Inc., and Inamed Corporation, In the Matter of
The consent order requires that Allergan and Inamed divest the rights to develop and distribute Reloxin, a potential Botox rival, to settle charges that Allergan’s $3.2 billion purchase of Inamed would reduce competition and force consumers to pay higher prices for botulinum toxin type A products. Under the terms of the FTC settlement, the companies will return the development and distribution rights to Reloxin to Ipsen Ltd., its U.K.- based manufacturer.
Commission Approves Final Consent Order in Matter of Allergan/Inamed
Maintaining Competition, FTC Allows Fresenius $3.5 Billion Deal to Buy Rival Dialysis Provider Renal Care Group
FTC Proposes Study of Competitive Impacts of Authorized Generic Drugs
Hospitals Plan for Collective Bargaining of Physicians Fees Likely Would Violate Federal Laws, FTC Staff Says
Health Care Alliance of Laredo, L.C., In the Matter of
Preserving Competition, FTC Requires Divestiture Before Allowing Allergans Acquisition of Inamed
Teva Pharmaceutical Industries Ltd. and IVAX Corporation, In the Matter of
The consent order allowed Teva to acquire IVAX Corporation, provided the companies sell the rights and assets needed to manufacture and market 15 generic pharmaceutical products. Among the drugs sold were several forms of generic amoxicillin and amoxicillin clavulanate potassium that are widely used in the United States.
FTC Staff Files Comments on New Jerseys Proposed Advertising Guideline 4; Commission Finalizes Teva/Ivax Consent Order
Texas Doctors' IPA Agrees to Settle Price Fixing Charges
Davita Inc. Submits Petition for Approval of Proposed Divestiture; FTC Submits Budget Request and Performance Plans to Congress
Announced Action for January 27, 2006
Preserving Competition, FTC Requires Divestitures Before Allowing Tevas $7.4 Billion Acquisition of IVAX
Commission Finds That North Texas Specialty Physicians Illegally Fixed Prices
In re Tamoxifen Citrate Antitrust Litigation
Displaying 1121 - 1140 of 1557